Table of Content

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.2.1 MARKET SCOPE 21
1.2.2 MARKETS COVERED 22
1.2.3 YEARS CONSIDERED FOR THE STUDY 23
1.3 CURRENCY 23
1.4 LIMITATIONS 23
1.5 STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.2 RESEARCH METHODOLOGY STEPS 24
2.2.1 SECONDARY DATA 26
2.2.1.1 Secondary sources 26
2.2.2 PRIMARY DATA 27
2.2.2.1 Primary sources 29
2.2.3 KEY INSIGHTS FROM PRIMARY SOURCES 30
2.2.4 MARKET SIZE ESTIMATION METHODOLOGY 31
2.2.5 REVENUE MAPPING-BASED MARKET ESTIMATION 32
2.2.6 MARKET DATA ESTIMATION AND TRIANGULATION 33
2.2.7 ASSUMPTIONS OF THE STUDY 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 38
4.1 NORTH AMERICAN NUCLEAR MEDICINE MARKET OVERVIEW 38
4.2 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE (2019) 39
4.3 NORTH AMERICAN DIAGNOSTIC PROCEDURES MARKET, BY TYPE (2019–2024) 39
4.4 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE (2019–2024) 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 DRIVERS 42
5.2.1.1 Increasing incidence and prevalence of target conditions 42
5.2.1.2 Alpha radioimmunotherapy-based targeted cancer treatment 42
5.2.1.3 Initiatives to reduce the demand-supply gap of Mo-99 42
?
5.2.2 RESTRAINTS 43
5.2.2.1 Short half-life of radiopharmaceuticals 43
5.2.3 OPPORTUNITIES 44
5.2.3.1 Use of radiopharmaceuticals in neurological applications 44

6 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: PIPELINE ASSESSMENT 45
6.1 INTRODUCTION 45
6.2 DIAGNOSTIC RADIOISOTOPES 46
6.3 THERAPEUTIC RADIOISOTOPES 48

7 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 51
7.1 INTRODUCTION 52
7.2 DIAGNOSTIC NUCLEAR MEDICINE 52
7.2.1 SPECT RADIOPHARMACEUTICALS 53
7.2.1.1 TC-99M 56
7.2.1.1.1 TC-99M commanded the largest share of the North American SPECT radiopharmaceuticals market 56
7.2.1.2 I-123 57
7.2.1.2.1 I-123 to register the highest growth rate during the forecast period 57
7.2.1.3 Tl-201 58
7.2.1.3.1 Tl-201 is useful in the management of heart patients and aids in determining the requirement for bypass surgery 58
7.2.1.4 Ga-67 58
7.2.1.4.1 GA-67 is used in the diagnosis of lymphoma and hepatoma 58
7.2.1.5 Other SPECT isotopes 59
7.2.2 PET RADIOPHARMACEUTICALS 59
7.2.2.1 F-18 60
7.2.2.1.1 F-18 commanded the largest share of the North American PET radiopharmaceuticals market 60
7.2.2.2 Rb-82 61
7.2.2.2.1 Increasing number of PET procedures and high accuracy offered by the Rb-82 isotope to drive the growth of this market 61
7.2.2.3 Other PET isotopes 61
7.3 THERAPEUTIC NUCLEAR MEDICINE 62
7.3.1 ALPHA EMITTERS 63
7.3.1.1 Ra-223 63
7.3.1.1.1 Ra-223 to witness significant growth in the forecast period owing to its targeted properties over beta emitters 63
?
7.3.2 BETA EMITTERS 63
7.3.2.1 Iodine-131 64
7.3.2.1.1 Iodine-131 accounted for the largest share of the beta emitters market 64
7.3.2.2 Y-90 65
7.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment 65
7.3.2.3 SM-153 65
7.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment 65
7.3.2.4 LU-177 66
7.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment 66
7.3.2.5 RH-186 67
7.3.2.5.1 RH-186 is commonly used for bone pain relief 67
7.3.2.6 Other beta emitters 67
7.3.3 BRACHYTHERAPY ISOTOPES 68
7.3.3.1 Iodine-125 69
7.3.3.1.1 I-125 accounted for the largest share of the North American brachytherapy isotopes market 69
7.3.3.2 Iridium-192 69
7.3.3.2.1 IR-192 is used to treat prostate cancer, skin cancer, sarcoids, and oral cancer 69
7.3.3.3 Palladium-103 70
7.3.3.3.1 PD-103 is best suited to treat aggressive tumors 70
7.3.3.4 Cesium-131 71
7.3.3.4.1 CS-131 is commonly used in gynecological applications 71
7.3.3.5 Other brachytherapy isotopes 71

8 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 72
8.1 INTRODUCTION 73
8.2 DIAGNOSTIC APPLICATIONS 73
8.2.1 SPECT APPLICATIONS 74
8.2.1.1 Cardiology 74
8.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans 74
8.2.1.2 Bone scans 75
8.2.1.2.1 Precision of SPECT in bone scanning has driven dependence on the technology 75
8.2.1.3 Pulmonary scans 75
8.2.1.3.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications 75
?
8.2.1.4 Thyroid applications 76
8.2.1.4.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment 76
8.2.1.5 Other SPECT applications 77
8.2.2 PET APPLICATIONS 77
8.2.2.1 Oncology 78
8.2.2.1.1 Increasing cancer incidence will fuel market growth 78
8.2.2.2 Cardiology 78
8.2.2.2.1 Growing preference for FDG in cardiac imaging is likely to boost market growth 78
8.2.2.3 Neurology 79
8.2.2.3.1 R&D on Alzheimer’s disease has positively affected the demand for nuclear medicine 79
8.2.2.4 Other PET applications 79
8.3 THERAPEUTIC APPLICATIONS 80
8.3.1 THYROID INDICATIONS 80
8.3.1.1 Increasing prevalence of thyroid disorders will fuel market growth 80
8.3.2 BONE METASTASIS 81
8.3.2.1 Introduction of novel therapies for bone metastasis will positively impact the market 81
8.3.3 ENDOCRINE TUMORS 82
8.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications 82
8.3.4 LYMPHOMA 82
8.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities 82
8.3.5 OTHER INDICATIONS 83

9 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT 84
9.1 INTRODUCTION 85
9.2 DIAGNOSTIC PROCEDURES 85
9.2.1 SPECT PROCEDURES 86
9.2.2 PET PROCEDURES 86
9.3 THERAPEUTIC PROCEDURES 86
9.3.1 BETA EMITTER PROCEDURES 87
9.3.2 ALPHA EMITTER PROCEDURES 87
9.3.3 BRACHYTHERAPY PROCEDURES 88
?

10 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY 89
10.1 INTRODUCTION 90
10.1.1 US 94
10.1.1.1 The US holds the largest share of the North American market 94
10.1.2 CANADA 99
10.1.2.1 Investments to secure medical isotope supply are likely to boost market growth 99

11 COMPETITIVE LANDSCAPE 103
11.1 OVERVIEW 103
11.2 MARKET RANKING ANALYSIS 104
11.3 COMPETITIVE LEADERSHIP MAPPING 105
11.3.1 VISIONARY LEADERS 105
11.3.2 INNOVATORS 106
11.3.3 DYNAMIC DIFFERENTIATORS 106
11.3.4 EMERGING COMPANIES 106
11.4 COMPETITIVE SCENARIO 108
11.4.1 PRODUCT LAUNCHES & APPROVALS 108
11.4.2 FUNDING 108
11.4.3 ACQUISITIONS 109
11.4.4 AGREEMENTS 109
11.4.5 PARTNERSHIPS 110
11.4.6 COLLABORATIONS 110
12 COMPANY PROFILES 111
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 CARDINAL HEALTH 111
12.2 CURIUM 113
12.3 GE HEALTHCARE 116
12.4 LANTHEUS MEDICAL IMAGING, INC. 119
12.5 BAYER AG 121
12.6 BRACCO IMAGING S.P.A. 122
12.7 ECZACIBA?I-MONROL NUCLEAR PRODUCTS 123
12.8 NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL) 124
12.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS) 125
12.10 NTP RADIOISOTOPES SOC, LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 127
12.11 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE) 128
12.12 NORTHSTAR MEDICAL RADIOISOTOPES, LLC 129
12.13 ECKERT & ZIEGLER 130
12.14 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA) 131
12.15 PHARMALOGIC 133
12.16 INSTITUTE OF ISOTOPES CO., LTD. 134
12.17 SINOTAU PHARMACEUTICALS GROUP 135
12.18 ISOTOPIA MOLECULAR IMAGING LIMITED 136
12.19 SHINE MEDICAL TECHNOLOGIES 137
12.20 GLOBAL MEDICAL SOLUTIONS, LTD. 138
12.21 FDA-APPROVED RADIOPHARMACEUTICALS 139
12.22 RIGHT-TO-WIN 145
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 146
13.1 DISCUSSION GUIDE 146
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 152
13.3 AVAILABLE CUSTOMIZATIONS 154
13.4 RELATED REPORTS 154
13.5 AUTHOR DETAILS 155



List of Figures



FIGURE 1 RESEARCH METHODOLOGY: NORTH AMERICAN NUCLEAR MEDICINE MARKET 24
FIGURE 2 RESEARCH DESIGN 25
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 28
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (1/2) 31
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (2/2) 32
FIGURE 6 DATA TRIANGULATION METHODOLOGY 33
FIGURE 7 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE 2019 VS. 2024 (USD MILLION) 35
FIGURE 8 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE 2019 VS. 2024 (USD MILLION) 36
FIGURE 9 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE 2019 VS. 2024 (USD MILLION) 36
FIGURE 10 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION 2019 VS. 2024 (USD MILLION) 37
FIGURE 11 HIGH PREVALENCE OF CANCER TO DRIVE THE MARKET DURING
THE FORECAST PERIOD 38
FIGURE 12 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN NUCLEAR MEDICINE MARKET 39
FIGURE 13 SPECT PROCEDURES TO ACCOUNT FOR THE LARGEST SHARE OF
THE MARKET IN 2024 39
FIGURE 14 ALPHA EMITTERS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET IN 2024 40
FIGURE 15 NORTH AMERICAN NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 41
FIGURE 16 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025 45
FIGURE 17 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE, 2011–2025 46
FIGURE 18 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025 46
FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY APPLICATION, 2011–2025 47
FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY PHASE, 2011–2025 48
FIGURE 21 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025 48
FIGURE 22 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION, 2011–2025 49
FIGURE 23 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025 50
FIGURE 24 NORTH AMERICAN NUCLEAR MEDICINE MARKET SNAPSHOT 90
FIGURE 25 KEY DEVELOPMENTS IN THE NORTH AMERICAN NUCLEAR MEDICINE MARKET, 2017–2019 103
FIGURE 26 NORTH AMERICAN NUCLEAR MEDICINE MARKET RANKING (2018) 104
FIGURE 27 NORTH AMERICAN NUCLEAR MEDICINE MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018) 107
FIGURE 28 CARDINAL HEALTH: COMPANY SNAPSHOT (2018) 111
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2018) 116
?
FIGURE 30 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2018) 119
FIGURE 31 BAYER AG: COMPANY SNAPSHOT (2018) 121
FIGURE 32 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2018) 130

 

List of Tables



TABLE 1 NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD 43
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS 43
TABLE 3 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 52
TABLE 4 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 52
TABLE 5 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET BY COUNTRY 2017–2024 (USD MILLION) 53
TABLE 6 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES 53
TABLE 7 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 56
TABLE 8 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 56
TABLE 9 NORTH AMERICAN TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 57
TABLE 10 NORTH AMERICAN I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 57
TABLE 11 NORTH AMERICAN TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 12 NORTH AMERICAN GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 13 NORTH AMERICAN OTHER SPECT ISOTOPES MARKET, BY COUNTRY 2017–2024 (USD MILLION) 59
TABLE 14 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 60
TABLE 15 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 60
TABLE 16 NORTH AMERICAN F-18 MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 17 NORTH AMERICAN RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 61
TABLE 18 NORTH AMERICAN OTHER PET ISOTOPES MARKET, BY COUNTRY 2017–2024 (USD MILLION) 62
TABLE 19 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 62
TABLE 20 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 62
TABLE 21 NORTH AMERICAN RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 63
TABLE 22 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION) 64
TABLE 23 NORTH AMERICAN BETA EMITTERS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 64
TABLE 24 NORTH AMERICAN IODINE-131 MARKET, BY COUNTRY 2017–2024 (USD MILLION) 65
TABLE 25 NORTH AMERICAN Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 65
TABLE 26 NORTH AMERICAN SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 27 NORTH AMERICAN LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 28 NORTH AMERICAN RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 67
TABLE 29 NORTH AMERICAN OTHER BETA EMITTERS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 67
TABLE 30 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE 2017–2024 (USD MILLION) 68
TABLE 31 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY 2017–2024 (USD MILLION) 69
TABLE 32 NORTH AMERICAN I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 33 NORTH AMERICAN IRIDIUM-192 MARKET, BY COUNTRY 2017–2024 (USD MILLION) 70
TABLE 34 NORTH AMERICAN PALLADIUM-103 MARKET, BY COUNTRY 2017–2024 (USD MILLION) 70
TABLE 35 NORTH AMERICAN CESIUM-131 MARKET, BY COUNTRY 2017–2024 (USD MILLION) 71
TABLE 36 NORTH AMERICAN OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 37 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 73
TABLE 38 NORTH AMERICAN DIAGNOSTIC APPLICATIONS MARKET, BY TYPE 2017–2024 (USD MILLION) 73
TABLE 39 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE 2017–2024 (USD MILLION) 74
TABLE 40 NORTH AMERICAN SPECT CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 75
TABLE 41 NORTH AMERICAN SPECT BONE SCANS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 75
TABLE 42 NORTH AMERICAN SPECT PULMONARY SCANS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 76
TABLE 43 NORTH AMERICAN SPECT THYROID APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 76
TABLE 44 NORTH AMERICAN OTHER SPECT APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 77
TABLE 45 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE 2017–2024 (USD MILLION) 77
TABLE 46 NORTH AMERICAN PET ONCOLOGY APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 78
TABLE 47 NORTH AMERICAN PET CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 78
TABLE 48 NORTH AMERICAN PET NEUROLOGY APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 79
TABLE 49 NORTH AMERICAN OTHER PET APPLICATIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 79
TABLE 50 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE APPLICATIONS MARKET BY INDICATION, 2017–2024 (USD MILLION) 80
TABLE 51 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 81
TABLE 52 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR BONE METASTASIS, BY COUNTRY, 2017–2024 (USD MILLION) 81
TABLE 53 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMORS, BY COUNTRY, 2017–2024 (USD MILLION) 82
TABLE 54 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR LYMPHOMA, BY COUNTRY, 2017–2024 (USD MILLION) 82
TABLE 55 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 83
TABLE 56 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY PROCEDURE 2019–2024 (THOUSAND PROCEDURES) 85
TABLE 57 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE PROCEDURES MARKET BY TYPE, 2019–2024 (THOUSAND PROCEDURES) 85
TABLE 58 NORTH AMERICAN SPECT PROCEDURES MARKET, BY RADIOISOTOPE 2019–2024 (THOUSAND PROCEDURES) 86
TABLE 59 NORTH AMERICAN PET PROCEDURES MARKET, BY RADIOISOTOPE 2019–2024 (THOUSAND PROCEDURES) 86
TABLE 60 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE 2019–2024 (THOUSAND PROCEDURES) 87
TABLE 61 NORTH AMERICAN BETA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES) 87
TABLE 62 NORTH AMERICAN ALPHA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES) 87
TABLE 63 NORTH AMERICAN BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES) 88
TABLE 64 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY COUNTRY 2017–2024 (USD MILLION) 91
TABLE 65 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 91
TABLE 66 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 91
TABLE 67 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 92
TABLE 68 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE 2017–2024 (USD MILLION) 92
TABLE 69 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 92
TABLE 70 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE 2017–2024 (USD MILLION) 93
TABLE 71 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 93
TABLE 72 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION) 93
TABLE 73 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE 2017–2024 (USD MILLION) 94
TABLE 74 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION 2017–2024 (USD MILLION) 94
TABLE 75 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION) 95
TABLE 76 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 95
TABLE 77 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 96
TABLE 78 US: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION) 96
TABLE 79 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION) 96
TABLE 80 US: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 81 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 97
TABLE 82 US: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 83 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION) 98
TABLE 84 US: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION 2017–2024 (USD MILLION) 98
TABLE 85 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION) 99
TABLE 86 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 100
TABLE 87 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 100
TABLE 88 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION) 100
TABLE 89 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE 2017–2024 (USD MILLION) 101
TABLE 90 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 91 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE 2017–2024 (USD MILLION) 101
TABLE 92 CANADA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION) 102
TABLE 93 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE 2017–2024 (USD MILLION) 102
TABLE 94 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION 2017–2024 (USD MILLION) 102
TABLE 95 PRODUCT LAUNCHES & APPROVALS (2017–2019) 108
TABLE 96 FUNDING (2017–2019) 108
TABLE 97 ACQUISITIONS (2017–2019) 109
TABLE 98 AGREEMENTS (2017–2019) 109
TABLE 99 PARTNERSHIPS (2017–2019) 110
TABLE 100 COLLABORATIONS (2017–2019) 110